173 related articles for article (PubMed ID: 29575038)
1. Hospital volume and short-term outcomes after cytoreductive nephrectomy.
Xia L; Strother MC; Taylor BL; Chelluri RR; Pulido JE; Guzzo TJ
J Surg Oncol; 2018 Jun; 117(7):1589-1596. PubMed ID: 29575038
[TBL] [Abstract][Full Text] [Related]
2. Hospital volume and outcomes of robot-assisted partial nephrectomy.
Xia L; Pulido JE; Chelluri RR; Strother MC; Taylor BL; Raman JD; Guzzo TJ
BJU Int; 2018 Jun; 121(6):900-907. PubMed ID: 29232025
[TBL] [Abstract][Full Text] [Related]
3. Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Heng DY; Wells JC; Rini BI; Beuselinck B; Lee JL; Knox JJ; Bjarnason GA; Pal SK; Kollmannsberger CK; Yuasa T; Srinivas S; Donskov F; Bamias A; Wood LA; Ernst DS; Agarwal N; Vaishampayan UN; Rha SY; Kim JJ; Choueiri TK
Eur Urol; 2014 Oct; 66(4):704-10. PubMed ID: 24931622
[TBL] [Abstract][Full Text] [Related]
4. Impact of Primary Tumor Size on Prognosis in Patients With Metastatic Renal Cell Carcinoma Receiving Cytoreductive Nephrectomy: A Population Study of a Chinese Center and the US SEER Database.
Jiang W; Shou J; Shi H; Wen L; Zhang H; Zheng S; Li C; Ma J
Technol Cancer Res Treat; 2021; 20():15330338211019507. PubMed ID: 34032149
[TBL] [Abstract][Full Text] [Related]
5. Mortality and morbidity after cytoreductive nephrectomy for metastatic renal cell carcinoma: a population-based study.
Abdollah F; Sun M; Thuret R; Schmitges J; Shariat SF; Perrotte P; Montorsi F; Karakiewicz PI
Ann Surg Oncol; 2011 Oct; 18(10):2988-96. PubMed ID: 21499808
[TBL] [Abstract][Full Text] [Related]
6. The independent oncological role for cytoreductive nephrectomy in metastatic renal cell carcinoma: Prognostic features in the era of targeted therapies.
Claeys T; Lumen N; Kumps C; Praet M; De Meerleer G; Rottey S; Ost P; Devisschere P; Villeirs G; Fonteyne V; Decaestecker K
Urol Oncol; 2017 Apr; 35(4):152.e13-152.e22. PubMed ID: 28153420
[TBL] [Abstract][Full Text] [Related]
7. Cytoreductive nephrectomy for metastatic renal cell carcinoma: a population-based analysis of perioperative outcomes according to clinical stage.
Takagi T; Sugihara T; Yasunaga H; Horiguchi H; Fushimi K; Kondo T; Homma Y; Tanabe K
Int J Urol; 2014 Aug; 21(8):770-5. PubMed ID: 24712555
[TBL] [Abstract][Full Text] [Related]
8. Normalization of C-reactive protein levels following cytoreductive nephrectomy in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors is associated with improved overall survival.
Teishima J; Ohara S; Shinmei S; Inoue S; Hayashi T; Mochizuki H; Mita K; Shigeta M; Matsubara A
Urol Oncol; 2018 Jul; 36(7):339.e9-339.e15. PubMed ID: 29773493
[TBL] [Abstract][Full Text] [Related]
9. Cytoreductive nephrectomy with thrombectomy before targeted therapy improves survival for metastatic renal cell carcinoma with venous tumor thrombus: a single-center experience.
Qi N; Wu P; Chen J; Li T; Ning X; Wang J; Gong K
World J Surg Oncol; 2017 Jan; 15(1):4. PubMed ID: 28056988
[TBL] [Abstract][Full Text] [Related]
10. Investigating the effect of treatment at high-volume hospitals on overall survival following cytoreductive nephrectomy.
Berg S; Cole AP; Fletcher SA; Pucheril D; Nabi J; Lipsitz SR; Chang SL; Sun M; Noldus J; Harshman LC; Choueiri TK; Trinh QD
Urol Oncol; 2018 Sep; 36(9):400.e15-400.e22. PubMed ID: 30274640
[TBL] [Abstract][Full Text] [Related]
11. Higher perioperative morbidity and in-hospital mortality in patients with end-stage renal disease undergoing nephrectomy for non-metastatic kidney cancer: a population-based analysis.
Schmitges J; Trinh QD; Sun M; Hansen J; Bianchi M; Jeldres C; Perrotte P; Dahlem R; Shariat SF; Chun FK; Montorsi F; Menon M; Fisch M; Graefen M; Karakiewicz PI
BJU Int; 2012 Sep; 110(6 Pt B):E183-90. PubMed ID: 22321256
[TBL] [Abstract][Full Text] [Related]
12. Partial nephrectomy seems to confer a survival benefit relative to radical nephrectomy in metastatic renal cell carcinoma.
Mazzone E; Nazzani S; Preisser F; Tian Z; Marchioni M; Bandini M; Capitanio U; Kapoor A; Tilki D; Montorsi F; Shariat SF; Saad F; Briganti A; I Karakiewicz P
Cancer Epidemiol; 2018 Oct; 56():118-125. PubMed ID: 30173050
[TBL] [Abstract][Full Text] [Related]
13. In-hospital mortality and failure to rescue after cytoreductive nephrectomy.
Trinh QD; Bianchi M; Hansen J; Tian Z; Abdollah F; Shariat SF; Montorsi F; Perrotte P; Karakiewicz PI; Sun M
Eur Urol; 2013 Jun; 63(6):1107-14. PubMed ID: 22981674
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive Characterization of the Perioperative Morbidity of Cytoreductive Nephrectomy.
Gershman B; Moreira DM; Boorjian SA; Lohse CM; Cheville JC; Costello BA; Leibovich BC; Thompson RH
Eur Urol; 2016 Jan; 69(1):84-91. PubMed ID: 26044802
[TBL] [Abstract][Full Text] [Related]
15. Rates and Predictors of Perioperative Complications in Cytoreductive Nephrectomy: Analysis of the Registry for Metastatic Renal Cell Carcinoma.
Roussel E; Campi R; Larcher A; Verbiest A; Antonelli A; Palumbo C; Derweesh I; Ghali F; Bradshaw A; Meagher MF; Heck M; Amiel T; Kriegmair MC; Rubio J; Musquera M; D'Anna M; Autorino R; Guruli G; Veccia A; Linares-Espinos E; Van Bruwaene S; Hevia V; Porpiglia F; Checcucci E; Minervini A; Mari A; Pavan N; Claps F; Marchioni M; Capitanio U; Beuselinck B; Mir MC; Albersen M;
Eur Urol Oncol; 2020 Aug; 3(4):523-529. PubMed ID: 32414697
[TBL] [Abstract][Full Text] [Related]
16. Survival after Cytoreductive Nephrectomy in Metastatic Non-clear Cell Renal Cell Carcinoma Patients: A Population-based Study.
Marchioni M; Bandini M; Preisser F; Tian Z; Kapoor A; Cindolo L; Primiceri G; Berardinelli F; Briganti A; Shariat SF; Schips L; Karakiewicz PI
Eur Urol Focus; 2019 May; 5(3):488-496. PubMed ID: 29229582
[TBL] [Abstract][Full Text] [Related]
17. The relationship of postoperative complications with in-hospital outcomes and costs after renal surgery for kidney cancer.
Kim SP; Leibovich BC; Shah ND; Weight CJ; Borah BJ; Han LC; Boorjian SA; Thompson RH
BJU Int; 2013 Apr; 111(4):580-8. PubMed ID: 22564425
[TBL] [Abstract][Full Text] [Related]
18. Oncologic Outcomes of Cytoreductive Nephrectomy in Synchronous Metastatic Renal-Cell Carcinoma: A Single-Center Experience.
Choi CI; Kang M; Sung HH; Jeon HG; Jeong BC; Jeon SS; Lee HM; Seo SIL
Clin Genitourin Cancer; 2018 Dec; 16(6):e1189-e1199. PubMed ID: 30262447
[TBL] [Abstract][Full Text] [Related]
19. Preoperative C-Reactive Protein Values as a Potential Component in Outcome Prediction Models of Metastasized Renal Cell Carcinoma Patients Receiving Cytoreductive Nephrectomy.
Kalogirou C; Mulfinger P; Sokolakis I; Krebs M; Kübler H; Riedmiller H; Vergho D
Urol Int; 2017; 99(3):297-307. PubMed ID: 28624829
[TBL] [Abstract][Full Text] [Related]
20. Benefit from cytoreductive nephrectomy and the prognostic role of neutrophil-to-lymphocyte ratio in patients with metastatic renal cell carcinoma.
Day D; Kanjanapan Y; Kwan E; Yip D; Lawrentschuk N; Davis ID; Azad AA; Wong S; Rosenthal M; Gibbs P; Tran B
Intern Med J; 2016 Nov; 46(11):1291-1297. PubMed ID: 27507629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]